دورية أكاديمية
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy
العنوان: | Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy |
---|---|
المؤلفون: | Galli G., Proto C., Signorelli D., Imbimbo M., Ferrara R., Prelaj A., De Toma A., Ganzinelli M., Zilembo N., De Braud F., Garassino M. C., Lo Russo G. |
المساهمون: | Galli, G., Proto, C., Signorelli, D., Imbimbo, M., Ferrara, R., Prelaj, A., De Toma, A., Ganzinelli, M., Zilembo, N., De Braud, F., Garassino, M. C., Lo Russo, G. |
سنة النشر: | 2019 |
المجموعة: | RE.PUBLIC@POLIMI - Research Publications at Politecnico di Milano |
مصطلحات موضوعية: | disease response, immunotherapy, long-term benefit, non-small-cell lung cancer, survival, Adult, Aged, 80 and over, Antineoplastic Agents, CTLA-4 Antigen, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunologic Factors, Lung Neoplasms, Male, Middle Aged, Programmed Cell Death 1 Receptor, Progression-Free Survival, Retrospective Studies |
الوصف: | Aim: A minority of patients gains advantage from immunotherapy (IO). Predictive variables of long-term benefit (LTB) are incompletely understood. Materials & methods: We retrospectively collected data about metastatic non-small-cell lung cancer patients treated with IO from April 2013 to July 2017. We defined LTB to IO as complete response (CR), partial response (PR) or disease stability as best response and maintaining it for ≥12 months. Results: Thirty-five of the 147 patients had LTB. More LTB patients than controls showed CR/PR as first and best response to IO. Only CR/PR as best response to IO retained association to LTB at multivariate analyses. Conclusion: Objective response appears as a central factor for LTB from IO. |
نوع الوثيقة: | article in journal/newspaper |
اللغة: | English |
العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31339060; info:eu-repo/semantics/altIdentifier/wos/WOS:000489271200008; volume:15; issue:23; firstpage:2743; lastpage:2757; numberofpages:15; journal:FUTURE ONCOLOGY; http://hdl.handle.net/11311/1170813Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85071182254 |
DOI: | 10.2217/fon-2019-0055 |
الإتاحة: | https://doi.org/10.2217/fon-2019-0055Test http://hdl.handle.net/11311/1170813Test |
حقوق: | info:eu-repo/semantics/openAccess |
رقم الانضمام: | edsbas.6AB770E7 |
قاعدة البيانات: | BASE |
DOI: | 10.2217/fon-2019-0055 |
---|